Developing a new treatment to inhibit SARS-CoV-2 and reduce COVID-19 related inflammation
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11177209
This study is working on a new type of medicine that could help fight COVID-19 by blocking a key enzyme the virus needs to multiply and reducing the inflammation that can make you feel worse, with the goal of making it easy to take as a pill.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11177209 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new class of small molecule inhibitors that target a specific enzyme involved in the replication of the SARS-CoV-2 virus and the excessive inflammatory response seen in COVID-19. The approach involves optimizing these inhibitors for effective oral delivery and testing their efficacy in laboratory settings. By understanding how the virus enters cells and how to block this process, the research aims to provide a dual-action treatment that could help manage both the viral infection and its associated complications.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals diagnosed with COVID-19 who are experiencing severe symptoms or complications.
Not a fit: Patients who have mild COVID-19 symptoms or those who have recovered from the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that effectively reduces COVID-19 severity and associated inflammatory responses.
How similar studies have performed: Other research has shown promise in targeting similar pathways for viral infections, indicating potential for success in this novel approach.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GLENN, JEFFREY S — STANFORD UNIVERSITY
- Study coordinator: GLENN, JEFFREY S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.